Nanog蛋白对前列腺癌雄激素剥夺治疗后进展速度的预测价值

Expression of Nanog in prostate cancer and its value in predicting the progressionfree survival of patients after androgen deprivation therapy

目的探讨前列腺癌Nanog基因的蛋白表达对雄激素剥夺治疗后进展的预测价值。方法选择2009年9月至2014年7月南通大学附属医院泌尿外科收治的前列腺癌患者,共115例,所有入组患者病理确诊后接受雄激素剥夺治疗,免疫组化EnVision染色方法检测前列腺穿刺癌组织中Nanog蛋白表达,χ2检验或Fisher精确概率检验分析临床病理因素与Nanog蛋白标记表达相关性,Nanog蛋白表达和传统临床病理因素分别进行单因素分析(Log-rank检验)和多因素分析(Cox比例风险模型)。结果Nanog蛋白表达与传统临床病理因素相关性分析发现治疗前PSA水平与Nanog蛋白水平相关。单因素生存分析和Cox比例风险模型多因素分析发现Nanog蛋白表达是雄激素剥夺治疗后进展的独立影响因素。结论 Nanog蛋白表达对前列腺癌雄激素剥夺治疗后进展速度有一定的预测价值。

Objective To evaluate the expression of Nanog in prostate cancer（PCa）and its value in predicting the progression-free survival time of patients after androgen deprivation therapy（ADT）.Methods The clinicopathological data of115 PCa cases receiving ADT treated during Sep.2009 and July 2014 in our hospital were retrospectively analyzed.The Nanog expression in paraffin-embeded tissue was detected with immunohistochemical EnVision method.The association between Nanog expression and clinicopathologic factors was evaluated withχ2 test or Fish exact test.The correlation between clinicopathologic factors and Nanog expression was analyzed with univariate and multivariate Cox proportional hazard model.Results Nanog expression significantly correlated with pretreatment serum PSA level.Univariate and multivariate analysis revealed that Nanog expression was independently associated with PSA progression after ADT.Conclusion Nanog serves as an independent prognostic factor for PCa patients receiving ADT.